The Government has joined forces with the pharmaceutical giant that makes weight loss jab Mounjaro in a bid to tackle obesity. The move could see patients accessing care at pharmacies or by using ...

People who took the daily pill orforglipron lost 12 percent of body weight on average after 72 weeks, according to clinical ...

Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36 mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Orforglipron Could Be the Next GLP-1 Pill to Win Approval The small-molecule weight loss and diabetes drug that is closest to approval by the U.S. Food and Drug Adminstration is called orforglipron.

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

SPA-FRANCORCHAMPS, Belgium (AP) — Lando Norris took pole position Saturday for Formula 1’s Belgian Grand Prix after Max Verstappen won the sprint race earlier in the day. Norris set the faste… ...

Orforglipron pills are expected to be approved by 2026, which, in my opinion, allows NOV to market its Rybelsus with less competitiveness.

2. Orforglipron's weight management results In April, Eli Lilly posted strong phase 3 results for its next-gen GLP-1 medicine, orforglipron, in diabetes patients.